In conclusion, Tregs appear to modulate astrocyte reactivity in AD-like amyloid pathology, by dampening C3+ A1-like phenotypes in favor of Cox2+ A2-like subsets of reactive astrocytes. The gene discussed is PTGS2; the disease is amyloidosis.